Curriculum

Name:	Emanuele Bosi

Place and date of birth:	Milan, 13 March 1954

Academic position:	Professor of Endocrinology, Vita-Salute San Raffaele University, Milan;

Hospital Position:	Head, General Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital, Milan;

Research Position:	Director, Diabetes Research Institute, San Raffaele Scientific Institute, Milan;

Degrees	M.D., University of Milan, 1979; Specialist Diploma in Diabetology and Metabolic Diseases, University of Milan, 1983; Specialist Diploma in Allergology and Clinical Immunology, University of Milan, 1987; Associate Professor of Internal Medicine, National Appointment Competition Call, 1992; Full Professor of Endocrinology, National Eligibility Competition Call, 2014. rally

Training:	1982-83 Hôpital Herriot, Lyon, Foreign University Assistant, field: pancreas transplantation; 1984-85 San Raffaele Institute, Milan, Research Assistant, field: diabetes; 1986-87 Middlesex Hospital & St. Bartholomew’s Hospital, London, Research Associate; field autoimmunity in diabetes and endocrine diseases;

Publications:	Author or coauthor in more than 150 publications.

Main Research Grants (since 2008):
Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2015-2017 ($ 300,000) Director, TrialNet International Clinical Center (NIDDK- National Institutes of Health, USA), 2003 to date ($2,083,335, as December 2014) Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2012-2014 ($ 214,500) Director, JDRF (Juvenile Diabetes Research Foundation, USA) International Site, 2009-2011 ($ 214,500) Principal Investigator, FORISID (Italian Diabetes Society Research Foundation) Research Grant: Gut immune regulation in patients with type 1 Diabetes, 2010 (€ 50,000) Director, JDRF (Juvenile Diabetes Research Foundation, USA) Italy/Germany TrialNet International Clinical Center, 2003-2008 ($ 301,000)

Invited lectures and seminars (since 2011)
‘La prevenzione del Diabete di tipo 1: TrialNet’. Convegno il diabete di tipo 1: passaggio dal pediatra al diabetologo. Sala Succetti, Confartigianato, Sondrio, 24 Gennaio 2013 ‘Il ruolo delle comorbidità nel trattamento del paziente diabetico’. Convegno telematico Il trattamento incretinico: non solo glicemia. NH Mantegna, Padova, 26 Gennaio 2013 ‘Challenges in diabetes management: evolving targets and therapeutics’ and ‘Addressing the challenges in the management of diabetes: safety of vildagliptin’. Galvus Galvus Met Speaker Masterclass, The Grand Hyatt Dubai Hotel, Dubai, 23-24 February 2013 ‘Predizione e Prevenzione del Diabete di Tipo 1’. Corso: Diabete mellito in età pediatrica: ricerca, ospedale, territorio. Badia Benedettina della Castagna, Genova, 16 Marzo 2013 ‘Nuove evidenze cliniche nell’uso di vildagliptin’. Convegno: Nuovi orizzonti in diabetologia. Grand Hotel Piazza Borsa, Palermo, 22 Marzo 2013 ‘Prevenzione cardiovascolare - Lo studio ORIGIN: il bicchiere mezzo vuoto’. XI° Corso Nazionale di Alta Formazione in Diabetologia: la terapia del diabete mellito. Hotel Giò, Perugia, 24 Marzo 2013 ‘Variabilità glicemica e nuovi approcci terapeutici nel diabete di tipo 2’. 12° Convegno Nazionale Diabete & Obesità. Atahotel Executive, Milano, 28 Marzo 2013 ‘Up & Down la qualità del controllo: il ruolo della variabilità glicemica nel Diabete Mellito tipo 2’. Convegno, Hotel Villa Baldi, Sestri Levante 5-6 Aprile 2013 ‘Il diabete in ospedale: gestione del rischio di ipoglicemia in pazienti critici’. Convegno: assistenza alla persona con diabete. La gestione terapeutica dall’ospedale al territorio. Regione Lombardia, Palazzo Pirelli, Sala Pirelli, Milano, 10 Aprile 2013 ‘Prevalence and consequences of hypoglycemia in patients with type 2 diabetes mellitus treated with oral antidiabetics’. ‘Novartis satellite symposium: balancing risks and benefits in the management of type 2 diabetes’, ADIT 2013, 5th International Conference on Advances in Diabetes and Insulin Therapy, Kempinski Hotel Zografski, Sofia, 12 April 2013 ‘What to use after metformin: DPP4-inhibitors’. ADIT 2013, 5th International Conference on Advances in Diabetes and Insulin Therapy, Kempinski Hotel Zografski, Sofia, 12 April 2013 ‘Farmacologia dei farmaci antidiabetici orali’. Visita al sito produttivo e aziendale di Novartis. Novartis headquarter, Basilea, 19 Aprile 2013 ‘MDI, possible with intelligent insulins’. 5^th Mantua Workshop on Diabetes Mellitus and related disorders. Teatro Scientifico Accademico del Bibiena, Mantova, 11 May 2013 ‘L'epidemiologia del diabete e i bisogni insoddisfatti del paziente diabetico’. Convegno Bristol-Myers Squibb Astra Zeneca: le nuove terapie, oltre il controllo glicemico. Sheraton Golf Parco De’ Medici, Roma, 13 Maggio 2013 ‘Defect of insulin secretion: a trigger factor in T2D manifestation and progression’. Novartis Satellite Symposium, All-Russian Congress of Endocrinology. Russian Academy of Sciences, Moscow, 22 May 2013 ‘Il ruolo del diabetologo nella prevenzione della retinopatia diabetica’. Corso: Diabete Sott’Occhio – Ospedale San Raffaele, Milano, 24 Maggio 2013 ‘DPP4-Inhibitors: what’s new’ and ‘Hypoglycemia in type 2 diabetes and cardiometabolic risk’. Cardiometabolic Risk Self-Assessment Program. Workshop of the Lebanese Society of Endocrinology Diabetes and Lipids, and Novartis Pharma Services. Phoenicia Intercontinental Hotel, Beirut, 25 May 2013 ‘Podium Disputation. Controllo glicemico nel paziente con diabete di tipo 2: è sufficiente HbA1c?’. Lettura Aziendale Novartis Farma, XIX° Congresso Nazionale AMD, Rome Marriott Park Hotel, Roma 31 Maggio 2013 ‘Galvus efficacy and differences with other DPP-4 inhibitors’. Glavus standalone symposium. JW Marriott Hotel, Seoul 4 June 2013 ‘Galvus efficacy and differences with other DPP-4 inhibitors’. Glavus standalone symposium. Lotte Hotel, Busan (Korea), 5 June 2013 ‘Autocontrollo nel diabetico di tipo 2: opportunità o spreco?’. Diabetes Summer School 2013. Il paziente DMT2 fragile: dall’anziano al soggetto con insufficienza renale. Frascati, 13 Giugno 2013 ‘Novità Terapeutiche: Quali altri ipoglicemizzanti’. XIX° Congresso AMD-SID Lombardia, Palace Hotel, Como, 14 Giugno 2013 ‘Strategies for the initial treatment of Diabetes mellitus: an approach with the goal to crack insulin-resistance’ and ‘Non pharmacological and pharmacological options: what is the evidence so far? Pre-diabetes and new onset diabetes: diabetologist perspective’. Diabetes Master-Class Project, sponsored by Berlin Chemie. Sheraton Hotel, Warsaw, 31 August 2013 ‘Role of glucose, blood pressure and lipids in diabetic retinopathy and DME’. International Preceptorship. DME: present and proposed approaches to therapeutics. San Raffaele Hospital, 4 September 2013 ‘Treating patients with type 2 diabetes: Putting safety first with vildagliptin’ and ‘Hot topics in type 2 diabetes management: Are our current definitions of hypoglycaemia reflecting both the risk to the patient and the patient’s well-being?’. AMAC Gold 2013, sponsored by Novartis. ITC Maurya Hotel, Delhi, 6-7 September 2013 ‘Advances in diabetes management’. AMAC Gold Great Minds Meet, sponsored by Novartis. Taj Palace Hotel, Delhi, 7 September 2013 ‘Nuove insuline: long acting’. Convegno SID Lombardia: nuovi farmaci per il diabetologo. Policlinico di Monza, Monza, 14 Settembre 2013 ‘Upcoming indications for metformin: what is the evidence?’. Berlin-Chemie Symposium: Modern aspects of the treatment of type 2 diabetes. Melia Barcelona Sarrià Hotel, Barcelona, 24 September 2013 ‘Challenges in diabetes management: evolving targets and therapeutics’ and ‘Key safety considerations for DPP4 inhibitors: focus on vildagliptin’. Galvus/GalvusMet Speaker Masterclass, Novotel Ambassador Hotel, Busan (Korea), 5-6 October 2013 ‘La terapia di combinazione insulina incretine’. Hot topics in Endocrinologia e Malattie del Metabolismo, Primo Meeting Lombardo. Bersi-Serlini, Provaglio d’Iseo, 11 Ottobre 2013 ‘Nuovi farmaci ipoglicemizzanti nel diabete di tipo 1: incretine e SGLT2-I’. SID Panorama Diabete – Forum Nazionale di Operatori e Professioni - Palazzo dei Congressi, Riccione, 21 Ottobre 2013 ‘Le nuove soluzioni terapeutiche superano i limiti delle attuali terapie?’. Simposio Aziendale Boehringer Ingelheim – Eli Lilly. Panorama Diabete – Forum Nazionale di Operatori e Professioni - Palazzo dei Congressi Riccione, 22 Ottobre 2013 ‘La terapia precoce con insulina nel diabete di tipo 2: uso, non uso e abuso’. Corso “4In – Terapia del Diabete: tradizione e innovazione - Castenedolo (BS) 30 Ottobre 2013 ‘Early intervention in type 2 diabetes’. Novartis Satellite Symposium of the Romanian Federation of Diabetes meeting, Teatrul Luceafarul, Iasi, 7 November 2013 ‘Revisione critica dei recent RCTs: SAVOR-TIMI e EXAMINE’. Costruzione della evidence-based medicine in diabetologia. Corso della Società Italiana di Diabetologia, Ospedale Maggiore Policlinico, Milano, 7 Febbraio 2014 ‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Seminars at: Dubai Diabetes Center, Dubai, 19 February 2014; Grand Millennium, Al Whada, Abu Dhabi, 19 February 2014; Imperial College Physicians, Grand Hyatt, Dubai, 21 February 2014 ‘Do we Still Need Tight Glycemic Control in Type 2 Diabetes?’. Plenary lecture, 4^th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014 ‘The Role of Insulin Therapy: When Do We Decide to Give it and How?’. Interactive workshop, 4^th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 20 February 2014 ‘Modern approaches to the management of type 2 diabetes: optimizing patient care’. Novartis Symposium,4^th Emirates Diabetes & Endocrine Congress. Grand Hyatt Conference & Convention Centre, Dubai, 21 February 2014 ‘Challenges in diabetes management: evolving targets and therapeutics’ and ‘Key safety considerations for DPP4 inhibitors: focus on vildagliptin’. Novartis AMAC Diabetes Speaker Masterclass Meeting, Hotel Intercontinental Dubai Festival City, Dubai, 28 February-1 March 2014 ‘Galvus®/Eucreas® as a therapeutic option in type 2 diabetes: What is the evidence?’. Novartis Region Europe Speaker Masterclass, Hotel California Champs Elysées, Paris, 27 March, 2014 ‘Structured SMBG in the management of type 2 diabetes’. Programa de excelencia en diabetes. International Exchange course. Hotel Vincci Soho, Madrid, 28 March 2014 ‘Strategies for the initial treatment of Diabetes mellitus: an approach with the goal to crack insulin-resistance’ and ‘Non pharmacological and pharmacological options: what is the evidence so far? Pre-diabetes and new onset diabetes: diabetologist perspective’. Berlin Chemie Diabetes Master-Class Project, Hilton Hotel, Sofia, 29 March 2014 ‘Le insuline basali iniettabili di oggi e di domani: le opzioni aumenteranno da 5 a 7. Come orientarsi nel diabete di tipo 1 e tipo 2?’. XII Corso di Alta Formazione in Diabetologia. Hotel Giò, Perugia, 30 Marzo 2014 ‘Flash Glucose Monitoring Technology from the clinician point of view’. Abbott FreeStyle Libre Kick Off Meeting. Hilton Diagonal Mar, Barcelona, 25 August 2014 ‘TrialNet in the world and at the San Raffaele’. Diabetes Research Institute Seminars, San Raffaele Scientific Institute, Milan, 11 September 2014 ‘Restoring blood glucose to normal values: importance for the progression of the disease’. Berlin Chemie EASD satellite meeting: New insights in and controversies about type 2 diabetes. Palais Ferstel, Vienna, 16 September 2014 ‘Consensus recommendations for the use of ambulatory glucose profile in clinical practice’. Flash Glucose Monitoring System Expert Meeting, Abbott Diabetes Care Center, Witney, Oxfordshire, 23 September 2014 ‘Rational basis and clinical results of Alogliptin and Pioglitazone association’. Takeda Pharmaceuticals Korea, Annual Business Meeting, The Westin Chosun Hotel, Busan, 26 September 2014 ‘Current updates on incretin-based therapy and emerging approaches in diabetes care’. The RED (Recent Evidences in Diabetes) Symposium, The Westin Chosun Hotel, Busan, 27 September 2014 ‘Treat to target: il modello del diabete’. Giornate reumatologiche d’autunno, Ospedale Santa Chiara di Trento, 2 Ottobre 2014 ‘I nuovi farmaci. Quale miglioramento? La rivoluzione del GLP-1’. IV Giornate Diabetologiche Luinesi, Centro Congressi Villa Cagnola, Gazzada Schianno, 11 Ottobre 2014 ‘Il mito dell’ansa chiusa’. Società Italiana di Diabetologia - VII Giornate Diabetologiche Sorrentine: dalla fisiopatologia alla gestione del paziente. Hilton Sorrento Palace, Sorrento, 18 Ottobre 2014 ‘Nuove prospettive terapeutiche nel diabete di tipo 2‘. Workshop – I bisogni insoddisfatti delle persone con diabete. Ospedale San Raffaele, Milano, 25 Ottobre 2014 ‘Screening e Prevenzione del Diabete di Tipo 1’. Convegno, Milano Tipo UNO, Hotel Hilton Milan, Milano, 30 Ottobre 2014 ‘Le Innovazioni Terapeutiche nella cura del Diabete di Tipo 1’. 2° Evento Brescia Diabete, Villa Fenaroli Palace Hotel , Rezzato (BS), 7 Novembre 2014 ‘The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. All-Russian Endocrinology Research Center, Moscow, 12 November 2014 ‘The Different Masks of Diabetes: focus on the adult autoimmune diabetes’. Annual School of Endocrinologists, Hotel Crowne Plaza St. Petersburg Airport, St. Petersburg, 14 November 2014 ‘Monitoraggio della Glicemia nel diabete di tipo 2 in terapia non insulinica: PRO’. Convegno SID Lombardia: Monitoraggio della Glicemia nel XXI Secolo, Policlinico di Monza, Monza, 11 Dicembre 2014